Feds reject Lilly's rheumatoid arthritis pill

Eli Lilly said U.S. regulators have rejected its much-anticipated pill for the immune disorder rheumatoid arthritis, the drugmaker’s second drug development setback since November. The Food and Drug Administration said in a letter to the company that it needed more information about the drug’s safety and the best doses, Lilly said Friday in a statement. Lilly said it disagrees with FDA’s conclusions but will work with the agency on a plan to eventually get the drug, baracitinib, approved for U.S...

Share this post